Pharmsynthesis

Pharmsynthesis is a Russian pharmaceutical company specializing in the development and production of drugs for treatment of socially significant diseases such as tuberculosis, HIV infection, oncology, diabetes and hepatitis. The company has been on the pharmaceutical market since 1997; its plants are located in Irkutsk, Ussuriysk, Tyumen, Bratsk and St. Petersburg.
Pharmsynthesis stock price chart
-31%
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Pharmsynthesis balance sheet

Report period2016 2017 2018 2019 2020 2021
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pharmsynthesis cash flows

Report period2016 2017 2018 2019 2020 2021
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

Pharmsynthesis multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pharmsynthesis profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pharmsynthesis assets
Pharmsynthesis cash flows
Pharmsynthesis dividends
0%

Pharmsynthesis shares

TickerNameTypeNominal valueISINPrice
LIFE:RMPharmsynthesisCommon shareRUB 5RU000A0JR514RUB 3.71

Pharmsynthesis expected events

DateTypeNoteSource
27.05.2022 17:00
Board of directors meeting
The Board of Directors will consider dividends for 2021 yearPictogram of www.e-disclosure.ru  www.e-disclosure.ru
Share capital structure of Pharmsynthesis
Pharmsynthesis news
16.05.2022
Pharmsintez company registered in Russia the drug sorafenib under the trade name Flutriksan. The drug suppresses tumor growth in metastatic renal cell, hepatocellular, differentiated thyroid cancer. The company will supply under an exclusive agreement with the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus. Sorafenib will be...
13.05.2022
Europe has followed the U.S. in approving a vaccine for all types of hepatitis B surface antigen from VBI Vaccines. The drug is the only differentiated adult hepatitis B vaccine approved for use worldwide. Registration of the drug in Russia is in the final stages and Pharmsintez is the exclusive distributor. The drug is expected to appear on the Russian mark...
29.04.2022
Pharmsintez's IFRS loss for 2021 was ₽697.55 million, up 32.9% from ₽524.814 million in the previous year. Revenue increased 17.9% to ₽438.33 million compared to ₽371.657 million a year earlier.
01.04.2022
Pharmsintez's RAS loss for 2021 was ₽1.326 billion, up 19.2% from ₽1.112 billion in the previous year. Revenue increased 46.7% to ₽293.965 billion compared to ₽200.321 billion a year earlier.
General information
Company namePharmsynthesis
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon
Mailing address188663 Rossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon, gorodskoy poselok Kuzmolovskiy, stanciya Kapitolovo, 134 str. 1
CEOPrilezhaev Efim Aleksandrovich
Phone329-80-80
Websitepharmsynthez.com
Information disclosuree-disclosure.ru